期刊
BIOCHEMICAL JOURNAL
卷 420, 期 -, 页码 83-91出版社
PORTLAND PRESS LTD
DOI: 10.1042/BJ20082140
关键词
CD30; inhibitor of apoptosis (IAP); lymphoma; nuclear factor kappa B (NF-kappa B); second mitochondrial-derived activator of caspase (Smac)/direct inhibitor of apoptosis-binding protein with low pI (DIABLO); tumour necrosis factor receptor-associated factor (TRAF)
资金
- University of Michigan
- National Institutes of Health [GM0678271, CAO9676]
- Sandler Foundation
c-IAP1 (cellular inhibitor of apoptosis 1) has recently emerged as a negative regulator of the non-canonical NF-kappa B (nuclear factor kappa B) signalling cascade. Whereas synthetic IAP inhibitors have been shown to trigger the autoubiquitination and degradation of c-IAP1, less is known about the physiological mechanisms by which c-IAP1 stability is regulated. In the present paper, we describe two distinct cellular processes that lead to the targeted loss of c-IAP1. Recruitment of a TRAF2 (tumour necrosis factor receptor-associated factor 2)-c-IAP1 complex to the cytoplasmic domain of the Hodgkin's/anaplastic large-cell lymphoma-associated receptor, CD30, leads to the targeting and degradation of the TRAF2-c-IAP1 heterodimer through a mechanism requiring the RING (really interesting new gene) domain of TRAF2, but not c-IAP1. In contrast, the induced autoubiquitination of c-IAP1 by IAP antagonists causes the selective loss of c-IAP1, but not TRAF2, thereby releasing TRAF2. Thus c-IAP1 can be targeted for degradation by two distinct processes, revealing the critical importance of this molecule as a regulator of numerous intracellular signalling cascades.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据